Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Danqi Tongluo decoction is a Traditional Chinese Medicine (TCM) herbal formula developed by Longhua Hospital, affiliated with the Shanghai University of Traditional Chinese Medicine. It is primarily utilized for the treatment of cervical spondylosis, particularly the radiculopathy subtype. The formula is designed based on TCM principles to tonify Qi, promote blood circulation, and unblock the collaterals (meridians). Key ingredients typically include *Salvia miltiorrhiza* (Danshen) and *Astragalus membranaceus* (Huangqi), which are recognized for their anti-inflammatory, antioxidant, and microcirculation-enhancing properties. In clinical research, it is often evaluated as an adjuvant therapy alongside electroacupuncture, cupping, and thermal therapy (TDP) to alleviate pain and improve functional outcomes in patients with cervical spine disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on danqi tongluo decoction.